Navigation Links
Actinium Pharmaceuticals to Present at EMIT Targeted Radiotherapy Conference

NEW YORK, Jan. 28, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, (OTC BB: CTVN), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, reported today that the program of the EMIT: Targeted Radiotherapy conference will feature three presentations devoted to Actinium Pharmaceuticals' clinical programs and technology platform.  These presentations will address broadening use of radiolabeled monoclonal antibodies for Hematopoietic Stem Cell Transplantation (HSCT) preparation in various indications; rationale for and prospects of a pivotal study of Iomab-B in relapsed and refractory acute myeloid leukemia (AML) patients; and successfully combining Actimab-A and low dose chemotherapy in front line treatment of older AML patients.

"These presentations demonstrate again both the progress we are making and the interest our product candidates and platforms elicit in the clinic for AML patients in particular," said Jack Talley , president and chief executive officer of Actinium.  "We intend to intensify our clinical programs this year and look forward to announcing additional milestones." 

The first Actinium program related presentation at this year's EMIT conference entitled "Radioimmunotherapy for Hematopoietic Cell Transplantation of Leukemia and Lymphoma: Emerging Therapy and Future Approaches" will focus on the expanding use in clinical trials of the CD45 targeting monoclonal antibody BC8 labeled with various radioisotopes for optimal match to the cancer being treated in the context of HSCT.  The second presentation entitled "Laying the Foundation for Stem Cell Transplantation with RIT for Enhanced Therapeutic Benefit" will focus on the unmet medical need of treating relapsed and refractory AML patients.  The third presentation "Targeted Alpha Particle Immunotherapy for Acute Myeloid Leukemia" will highlight results of front line treatment of older newly diagnosed AML patients. 

The following are the dates and times of the above referenced presentations:

January 30, 2013, 9.00 am: "Radioimmunotherapy for Hematopoietic Cell Transplantation of Leukemia and Lymphoma: Emerging Therapy and Future Approaches", presenter: John Pagel , MD, Associate Member, Clinical Research Division, Fred Hutchinson Cancer Center

January 31, 2013, 1.30 pm: "Laying the Foundation for Stem Cell Transplantation with RIT for Enhanced Therapeutic Benefit", presenter: Dragan Cicic , MD, COO & CMO, Actinium Pharmaceuticals

January 31, 2013, 2.00 pm: "Targeted Alpha Particle Immunotherapy for Acute Myeloid Leukemia", Joseph Jurcic , MD, Chief, Leukemia Services, New York Presbyterian/Columbia

The above referenced oral presentations will take place at the One Washington Circle Hotel, One Washington Circle , N.W. Washington , D.C. 20037.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. is a New York, New York based biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 isotopes in association with monoclonal antibodies.  The Company also develops other radiopharmaceuticals for select applications.

For more information:

Visit our web site or contact:

Jack Talley , CEO 
Actinium Pharmaceuticals Inc. 
Tel:  (646) 459-4201 

Jeff Ramson  
ProActive Capital Group, LLC 
Tel:  (646) 863-6341 

Dennis S. Dobson Jr. , 203-258-0159

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance.  No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

SOURCE Actinium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actinium Pharmaceuticals Inc. Pays Regulatory Milestone to Abbott Biotherapeutics Corp.
2. Actinium Pharmaceuticals Announces The Addition of The Fred Hutchinson Cancer Research Center To Actiniums Multicenter Clinical Trial For Patients With Acute Myeloid Leukemia
3. Actinium Pharmaceuticals and Philogen S.p.A. Announce Collaboration for Alpha Therapy Based Antiangiogenesis Program
4. Actinium Pharmaceuticals Strengthens Management Team
5. Actinium Pharmaceuticals Stockholders Vote to Approve Fundraising and Public Listing
6. Actinium Pharmaceuticals Commences Screening for the Second Cohort of Patients in the Companys Ongoing Phase I/II Trial in Acute Myeloid Leukemia
7. Gerri Henwood Joins Actinium Pharmaceuticals as Chief Development Officer
8. Actinium Pharmaceuticals Announces New Round of Financing
9. Actinium Pharmaceuticals Sponsors Webinar on Clinical Use of Alpha Immunotherapy
10. Additional Clinical Data from Two Trials on Actinium Pharmaceuticals Iomab-B to be Presented at American Society of Hematology (ASH) Annual Meeting
11. University of Pennsylvania joins Actinium Pharmaceuticals Multicenter Actimab-A Trial
Post Your Comments:
(Date:11/27/2015)... 2015 --> ... online. The potential to save costs, improve treatment quality ... from fully exploited as yet. Here, particular emphasis is ... via mobile tablet or directly at the patients, bedside. ... ) -->      (Photo: ...
(Date:11/27/2015)... Research and Markets ( ) has announced the ... report to their offering. ... author the present scenario and growth prospects of the ... market size, the report considers revenue generated from the ... copper IUDs. The report forecasts the global intrauterine devices ...
(Date:11/26/2015)... November 26, 2015 Un nuevo ... Bremachlorin para el cáncer avanzado.   --> ... terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... la inmunoterapia con la terapia fotodinámica de Bremachlorin para ... Research . --> Clinical Cancer Research . ...
Breaking Medicine Technology:
(Date:11/26/2015)... Toronto, ON and Cambridge, ON (PRWEB) , ... ... ... announced today the availability of a real-time eReferral system for diagnostic imaging in ... CTs, ultrasounds, X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied Drug Delivery ... to integrate dose form selection in early phase drug development. The first of ... and bringing together the UK’s emerging life sciences companies, corporate partners, and investors, ...
(Date:11/26/2015)... ... November 26, 2015 , ... PRMA Plastic Surgery is updating ... our surgeons performed their 6,000th free flap breast reconstruction surgery! , “What an accomplishment ... day excited to rebuild lives and it’s an honor to have served all of ...
(Date:11/26/2015)... ... 26, 2015 , ... Pixel Film Studios brings Final Cut ... Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired designs, with ... users limitless opportunities to stylize and create designs quickly and easily, all within ...
(Date:11/26/2015)... ... ... Indosoft Inc., developer and distributor of the world-class Asterisk based contact center ... reliability. , The new Q-Suite 6 platform is based on the latest Java Enterprise ... a specific piece of software for many key components of the suite. Much of ...
Breaking Medicine News(10 mins):